Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia

Kaneshige, Atsunori; Bai, Longchuan; Wang, Mi; McEachern, Donna; Meagher, Jennifer L.; Xu, Renqi; Kirchhoff, Paul D.; Wen, Bo; Sun, Duxin; Stuckey, Jeanne A.; Wang, Shaomeng

doi:10.1021/acs.jmedchem.2c01665

Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia

Journal Article · 02 February 2023 · Journal of Medicinal Chemistry

DOI:https://doi.org/10.1021/acs.jmedchem.2c01665· OSTI ID:2423386

Kaneshige, Atsunori ^[1]; Bai, Longchuan ^[2]; Wang, Mi ^[2]; McEachern, Donna ^[2]; Meagher, Jennifer L. ^[3]; Xu, Renqi ^[2]; Kirchhoff, Paul D. ^[2]; Wen, Bo ^[4]; ^[5]; Stuckey, Jeanne A. ^[6]; ^[7]

Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States; Department of Internal Medicine, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States
Department of Internal Medicine, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States
Life Science Institute, University of Michigan, Ann Arbor, Michigan 48109, United States
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States
Life Science Institute, University of Michigan, Ann Arbor, Michigan 48109, United States; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States; Department of Internal Medicine, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States; Department of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States

Not provided.

Research Organization:: Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: USDOE

DOE Contract Number:: AC02-06CH11357

OSTI ID:: 2423386

Journal Information:: Journal of Medicinal Chemistry, Journal Name: Journal of Medicinal Chemistry Journal Issue: 4 Vol. 66; ISSN 0022-2623

Publisher:: American Chemical Society (ACS)

Country of Publication:: United States

Language:: English

References (33)

Features and development of Coot Emsley, P.; Lohkamp, B.; Scott, W. G. Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 4 https://doi.org/10.1107/S0907444910007493	journal	March 2010
Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease Knight, J. Morgan; Mandal, Pijus; Morlacchi, Pietro Journal of Biological Chemistry, Vol. 293, Issue 26 https://doi.org/10.1074/jbc.RA117.000567	journal	June 2018
Phaser crystallographic software McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D. Journal of Applied Crystallography, Vol. 40, Issue 4 https://doi.org/10.1107/S0021889807021206	journal	July 2007
STATs: transcriptional control and biological impact Levy, David E.; Darnell, J. E. Nature Reviews Molecular Cell Biology, Vol. 3, Issue 9 https://doi.org/10.1038/nrm909	journal	September 2002
PROTACs: An Emerging Therapeutic Modality in Precision Medicine Nalawansha, Dhanusha A.; Crews, Craig M. Cell Chemical Biology, Vol. 27, Issue 8 https://doi.org/10.1016/j.chembiol.2020.07.020	journal	August 2020
Synthesis and in Vitro Evaluation of a Peptidomimetic Inhibitor Targeting the Src Homology 2 (SH2) Domain of STAT6 Morlacchi, Pietro; Mandal, Pijus K.; McMurray, John S. ACS Medicinal Chemistry Letters, Vol. 5, Issue 1 https://doi.org/10.1021/ml4003919	journal	December 2013
STAT5 is essential for IL-7–mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells Ribeiro, Daniel; Melão, Alice; van Boxtel, Ruben Blood Advances, Vol. 2, Issue 17 https://doi.org/10.1182/bloodadvances.2018021063	journal	September 2018
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future Pettersson, Mariell; Crews, Craig M. Drug Discovery Today: Technologies, Vol. 31 https://doi.org/10.1016/j.ddtec.2019.01.002	journal	April 2019
Nanomolar Inhibitors of the Transcription Factor STAT5b with High Selectivity over STAT5a Elumalai, Nagarajan; Berg, Angela; Natarajan, Kalaiselvi Angewandte Chemie International Edition, Vol. 54, Issue 16 https://doi.org/10.1002/anie.201410672	journal	February 2015
Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3 Mandal, Pijus K.; Gao, Fengqin; Lu, Zhen Journal of Medicinal Chemistry, Vol. 54, Issue 10 https://doi.org/10.1021/jm2000882	journal	April 2011
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice Walz, Christoph; Ahmed, Wesam; Lazarides, Katherine Blood, Vol. 119, Issue 15 https://doi.org/10.1182/blood-2011-12-397554	journal	April 2012
Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity Mandal, Pijus K.; Morlacchi, Pietro; Knight, J. Morgan Journal of Medicinal Chemistry, Vol. 58, Issue 22 https://doi.org/10.1021/acs.jmedchem.5b01321	journal	November 2015
Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein Cumaraswamy, Abbarna A.; Lewis, Andrew M.; Geletu, Mulu ACS Medicinal Chemistry Letters, Vol. 5, Issue 11 https://doi.org/10.1021/ml500165r	journal	October 2014
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia Maurer, Barbara; Nivarthi, Harini; Wingelhofer, Bettina Haematologica, Vol. 105, Issue 2 https://doi.org/10.3324/haematol.2019.216986	journal	May 2019
Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia Liao, Zhiyong; Gu, Lei; Vergalli, Jenny Molecular Cancer Therapeutics, Vol. 14, Issue 8 https://doi.org/10.1158/1535-7163.MCT-14-0883	journal	August 2015
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation Yoshimoto, Goichi; Miyamoto, Toshihiro; Jabbarzadeh-Tabrizi, Siamak Blood, Vol. 114, Issue 24 https://doi.org/10.1182/blood-2008-12-196055	journal	December 2009
The STATs of cancer — new molecular targets come of age Yu, Hua; Jove, Richard Nature Reviews Cancer, Vol. 4, Issue 2 https://doi.org/10.1038/nrc1275	journal	February 2004
SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression Zhou, Haibin; Bai, Longchuan; Xu, Renqi ACS Medicinal Chemistry Letters, Vol. 12, Issue 6 https://doi.org/10.1021/acsmedchemlett.1c00155	journal	May 2021
Three-dimensional structure of the Stat3β homodimer bound to DNA Becker, Stefan; Groner, Bernd; Müller, Christoph W. Nature, Vol. 394, Issue 6689 https://doi.org/10.1038/28101	journal	July 1998
Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity Page, Brent D. G.; Khoury, Haytham; Laister, Rob C. Journal of Medicinal Chemistry, Vol. 55, Issue 3 https://doi.org/10.1021/jm200720n	journal	January 2012
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo Bai, Longchuan; Zhou, Haibin; Xu, Renqi Cancer Cell, Vol. 36, Issue 5 https://doi.org/10.1016/j.ccell.2019.10.002	journal	November 2019
STAT5 in Cancer and Immunity Rani, Aradhana; Murphy, John J. Journal of Interferon & Cytokine Research, Vol. 36, Issue 4 https://doi.org/10.1089/jir.2015.0054	journal	April 2016
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo Kaneshige, Atsunori; Bai, Longchuan; Wang, Mi Nature Chemical Biology, Vol. 19, Issue 6 https://doi.org/10.1038/s41589-022-01248-4	journal	February 2023
Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization Nikolovska-Coleska, Zaneta; Wang, Renxiao; Fang, Xueliang Analytical Biochemistry, Vol. 332, Issue 2 https://doi.org/10.1016/j.ab.2004.05.055	journal	September 2004
FLT3 mutations in acute myeloid leukemia cell lines Quentmeier, H.; Reinhardt, J.; Zaborski, M. Leukemia, Vol. 17, Issue 1 https://doi.org/10.1038/sj.leu.2402740	journal	January 2003
STAT5 in hematopoietic stem cell biology and transplantation Wang, Zhengqi; Bunting, Kevin D. JAK-STAT, Vol. 2, Issue 4 https://doi.org/10.4161/jkst.27159	journal	October 2013
Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemia Hoelbl, Andrea; Schuster, Christian; Kovacic, Boris EMBO Molecular Medicine, Vol. 2, Issue 3 https://doi.org/10.1002/emmm.201000062	journal	March 2010
Pharmacologic inhibition of STAT5 in acute myeloid leukemia Wingelhofer, Bettina; Maurer, Barbara; Heyes, Elizabeth C. Leukemia, Vol. 32, Issue 5 https://doi.org/10.1038/s41375-017-0005-9	journal	February 2018
Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA Chen, Xiaomin; Vinkemeier, Uwe; Zhao, Yanxiang Cell, Vol. 93, Issue 5 https://doi.org/10.1016/S0092-8674(00)81443-9	journal	May 1998
JAK/STAT signaling in hematological malignancies Vainchenker, W.; Constantinescu, S. N. Oncogene, Vol. 32, Issue 21 https://doi.org/10.1038/onc.2012.347	journal	August 2012
Current strategies for the design of PROTAC linkers: a critical review Troup, Robert I.; Fallan, Charlene; Baud, Matthias G. J. Exploration of Targeted Anti-tumor Therapy, Vol. 1, Issue 5 https://doi.org/10.37349/etat.2020.00018	journal	October 2020
STAT5 signaling is required for the efficient induction and maintenance of CML in mice Ye, Dan; Wolff, Nicholas; Li, Li Blood, Vol. 107, Issue 12 https://doi.org/10.1182/blood-2005-10-4110	journal	June 2006
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein Zhou, Haibin; Bai, Longchuan; Xu, Renqi Journal of Medicinal Chemistry, Vol. 62, Issue 24 https://doi.org/10.1021/acs.jmedchem.9b01530	journal	November 2019

Similar Records

A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo

Journal Article · 2023 · Nature Chemical Biology · OSTI ID:2423268

Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader

Journal Article · 2024 · Journal of Medicinal Chemistry · OSTI ID:2581511

Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia

Journal Article · 2018 · Experimental Cell Research · OSTI ID:23082708

Related Subjects

Pharmacology & Pharmacy

Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia

Citation Formats

References (33)

Similar Records

Related Subjects